Previous 10 | Next 10 |
LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announce...
ProQR (NASDAQ: PRQR ): Q3 GAAP EPS of -€0.31 beats by €0.03 . More news on: ProQR Therapeutics N.V., Earnings news and commentary, Healthcare stocks news, Read more ...
Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10 Initial clinical data from Phase 1/2 trial of QR-421a for Usher syndrome type 2 on track for Q1 2020 QR-1123 Investigational New Drug application active for autosomal dominant retinitis pigmentosa €49...
LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced the closing of its previo...
Titan Medical (NASDAQ: TMDI ) -52% on filing amended prospectus and withdrawing previous milestones. More news on: Titan Medical Inc., Westwater Resources, Inc., TDH Holdings, Inc., Stocks on the move, Read more ...
Gainers: ABC +7.0% . CAH +8.1% . MCK +7.5% . SNBR +4.8%. ENDP +4.6% . More news on: AmerisourceBergen Corporation, Cardinal Health, Inc., McKesson Corporation, Stocks on the move, , News on ETFs Read more ...
The FDA grants Rare Pediatric Disease designation for ProQR Therapeutics' (NASDAQ: PRQR ) sepofarsen for the treatment of Leber congenital amaurosis type 10 (LCA10). More news on: ProQR Therapeutics N.V., Healthcare stocks news, Stocks on the move, Read more ...
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today announced that it received Rare Pediat...
The following slide deck was published by ProQR Therapeutics N.V. in conjunction with this Read more ...
ProQR Therapeutics (NASDAQ: PRQR ) announces positive topline results from a Phase 1/2 clinical trial evaluating sepofarsen (QR-110) in patients with Leber congenital amaurosis type 10 (LCA10) due to a certain mutation in the CEP290 gene. More news on: ProQR Therapeutics N.V., Healthca...
News, Short Squeeze, Breakout and More Instantly...
ProQR Therapeutics N.V. Company Name:
PRQR Stock Symbol:
NASDAQ Market:
ProQR Therapeutics N.V. Website:
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the An...
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will present new preclinical data for its proprietary Axiomer™ RNA edi...
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has again successfully defended against opposition filed against a key pate...